TERN TERNS PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended December 31, 2025, TERNS PHARMACEUTICALS INC reported revenue of n/a, net income of −$23.6M and diluted EPS of −$0.24; for the fiscal year ended December 2025 revenue was n/a.
TERN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$110M, net income −$96.2M (margin n/a), EPS −$1.03
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$102M, net income −$88.9M (margin n/a), EPS −$1.12
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$103M, net income −$90.2M (margin n/a), EPS −$1.27
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$62.0M, net income −$60.3M (margin n/a), EPS −$1.67
- Fiscal year ended Dec 2021: revenue $1.00M, gross profit n/a, operating income −$49.9M, net income −$50.2M (margin -5015.8%), EPS −$2.21
TERN quarterly revenue and earnings
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$23.6M, EPS −$0.24
- Quarter ended Sep 30, 2025: revenue n/a, net income −$24.6M, EPS −$0.27
- Quarter ended Jun 30, 2025: revenue n/a, net income −$24.1M, EPS −$0.26
- Quarter ended Mar 31, 2025: revenue n/a, net income −$23.9M, EPS −$0.26
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$21.8M, EPS −$0.23
- Quarter ended Sep 30, 2024: revenue n/a, net income −$21.9M, EPS −$0.28
- Quarter ended Jun 30, 2024: revenue n/a, net income −$22.7M, EPS −$0.31
- Quarter ended Mar 31, 2024: revenue n/a, net income −$22.4M, EPS −$0.30
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$21.0M, EPS −$0.29
- Quarter ended Sep 30, 2023: revenue n/a, net income −$29.8M, EPS −$0.42
- Quarter ended Jun 30, 2023: revenue n/a, net income −$17.9M, EPS −$0.25
- Quarter ended Mar 31, 2023: revenue n/a, net income −$21.5M, EPS −$0.31
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$15.8M, EPS −$0.13
- Quarter ended Sep 30, 2022: revenue n/a, net income −$16.8M, EPS −$0.44
- Quarter ended Jun 30, 2022: revenue n/a, net income −$13.9M, EPS −$0.55
- Quarter ended Mar 31, 2022: revenue n/a, net income −$13.8M, EPS −$0.55
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$14.2M, EPS −$0.43
- Quarter ended Sep 30, 2021: revenue n/a, net income −$11.8M, EPS −$0.47
- Quarter ended Jun 30, 2021: revenue n/a, net income −$10.7M, EPS −$0.43
- Quarter ended Mar 31, 2021: revenue n/a, net income −$13.3M, EPS −$0.88
TERN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$82.2M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$70.0M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$67.4M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$49.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$41.8M, share buybacks n/a
TERN balance sheet
- Dec 31, 2025: cash $525M, total assets $1.03B, total liabilities $18.6M, shareholders' equity $1.01B
- Sep 30, 2025: cash $151M, total assets $302M, total liabilities $17.6M, shareholders' equity $284M
- Jun 30, 2025: cash $146M, total assets $320M, total liabilities $15.2M, shareholders' equity $305M
- Mar 31, 2025: cash $139M, total assets $339M, total liabilities $13.3M, shareholders' equity $326M
- Dec 31, 2024: cash $161M, total assets $364M, total liabilities $18.1M, shareholders' equity $346M
- Sep 30, 2024: cash $270M, total assets $378M, total liabilities $13.8M, shareholders' equity $364M
- Jun 30, 2024: cash $91.5M, total assets $231M, total liabilities $12.2M, shareholders' equity $219M
- Mar 31, 2024: cash $65.1M, total assets $247M, total liabilities $10.0M, shareholders' equity $237M
Is TERN profitable?
No. TERNS PHARMACEUTICALS INC lost $96.2M over the last four quarters.
What is TERN's EPS?
Diluted earnings per share over the last four quarters were −$1.03; −$0.24 in the latest quarter.